Published

Asthma — optimising long-term management with inhaled corticosteroid ACG

Condition

Respiratory

Guidance type

ACG

15 October 2020

Published on 15 Oct 2020
Last Updated on 15 Oct 2020

This ACE Clinical Guideline (ACG) covers clinical assessment, pharmacological treatment, and non-pharmacological strategies for managing asthma over the long term, with a focus on inhaled corticosteroid as the mainstay. The accompanying Appendix provides a list of preventer medications registered for asthma in Singapore.

Download the ACG

Asthma Management - Optimising long-term management with inhaled corticosteroids (Oct 2020) [PDF] (opens in new tab)

Or click the link below for the web version

Asthma Management - Optimising long-term management with inhaled corticosteroids (Oct 2020) [WEB]

Request for a hardcopy

Click here (opens in new tab)

Registered doctors and pharmacists may claim 1 Continuing Medical Education (CME)/Continuing Professional Education (CPE) point under category 3A for reading each ACG.

ACG Recommendations

Regularly assess asthma symptoms and risk of poor asthma outcomes, including factors that can influence these.
Consider using a validated questionnaire to assess asthma symptoms.
Assess factors influencing asthma symptoms or risk of poor asthma outcomes. These can be remembered with the acronym BREATHE.
Use inhaled corticosteroid as the mainstay of long-term asthma management.
For patients aged 6 years and older, do not use short-acting beta2agonist alone (without a preventer) to treat asthma long term.
Use a stepwise approach when selecting or adjusting preventer treatment for asthma (see Figure 2 on page 6).
Educate all patients with asthma or their caregivers on how to self-manage.
Regularly follow up all patients with asthma.
Referral to a specialist could be made at any point.

ACG references and appendix

Feedback

Click here (opens in new tab) to give us feedback on this ACG.

Other related resources